Management of Ventricular Tachycardia in Pediatric Patients

Introduction to Treatment Guidelines

The American Academy of Pediatrics recommends that adenosine should not be used as first-line treatment for ventricular tachycardia (VT) in pediatric patients, as synchronized electrical cardioversion is the preferred initial therapy for unstable VT, while amiodarone may be considered for stable VT with careful hemodynamic monitoring 1

For unstable VT, the American Heart Association recommends synchronized electrical cardioversion as the preferred first therapy, starting at 0.5-1 J/kg and increasing to 2 J/kg if needed, and this should be performed immediately without delay for pharmacologic interventions 1, 3
For stable VT, amiodarone (5 mg/kg over 20-60 minutes) may be reasonable, though 71% of children experience cardiovascular side effects that are dose-related, and careful hemodynamic monitoring is mandatory during amiodarone administration 1, 2

A 12-lead ECG is essential to differentiate VT from SVT with aberrancy before any treatment, as wide-complex tachycardia often originates in the ventricles but may be supraventricular with aberrant conduction 2, 3
Never assume wide-complex tachycardia is supraventricular in origin—treat as VT until proven otherwise, as the diagnostic use of adenosine in wide-complex tachycardia carries significant risk if the rhythm is actually VT 2, 4

Adenosine is the drug of choice (Class I recommendation) specifically for supraventricular tachycardia with narrow QRS complexes (<0.09 seconds), with dosing for SVT: 0.1 mg/kg rapid IV bolus (maximum 6 mg first dose), followed by 0.2 mg/kg if needed, up to maximum 0.3 mg/kg 2, 5